论文部分内容阅读
肝脏恶性肿瘤是中国最常见的癌症死亡病因之一。钇-90微球选择性内放射治疗（n 90Y-SIRT）作为一种具有应用前景的局部微创治疗手段，其疗效及安全性已被近20年来的临床应用所证实，并被美国国立综合癌症网络等国际指南推荐用于肝脏恶性肿瘤患者的局部治疗。鉴于n 90Y-SIRT操作的复杂性，需要多学科协作提升治疗的安全性和成功率，中国临床肿瘤学会核医学专家委员会联合北京市核医学质量控制与改进中心组织了来自肿瘤外科、介入科、核医学科等相关领域专家共同商讨形成n 90Y-SIRT的临床诊治、管理共识，具体涉及定义、适应证和禁忌证、治疗流程、术后随访、不良反应及并发症、辐射安全管理等内容。特此供相关从业人员参考，以助各单位建立n 90Y-SIRT的规范化管理与治疗制度。n “,”Liver malignant tumors are one of the most common causes of cancer-related deaths in China. Selective internal yttrium-90 radioembolization therapy (n 90Y-SIRT) is a kind of promising local minimally invasive method, and its effectiveness and safety has been confirmed in clinical application over the past two decades. Moreover, it has been approved by the U.S. National Comprehensive Cancer Network and other international guidelines for the topical treatment of patients with liver malignancies. Taking into account the complexity of the n 90Y-SIRT and the need for multidisciplinary collaboration to improve the safety and success rate of treatment, the Nuclear Medicine Expert Committee of the Chinese society of Clinical Oncology, along with Beijing Nuclear Medicine Quality Control and Improvement Center invited experts from surgical oncology, interventional medicine, nuclear medicine, and other related fields to discuss and form a consensus on the clinical diagnosis, treatment and management, which mainly included definition, indications and contraindications, treatment procedures, postoperative follow-up, adverse reactions and complications, radiation safety management, etc. Herein, we provide the reference guidance to establish n 90Y-SIRT standardized management and treatment system various units for relevant practitioners.n